MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
IPO Year:
Exchange: NASDAQ
Website: mimedx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 3/7/2024 | $12.00 | Buy | Lake Street |
| 10/27/2023 | $12.00 | Buy | Craig Hallum |
| 10/13/2022 | $7.00 | Buy | Mizuho |
| 9/14/2021 | $20.00 → $8.50 | Buy | HC Wainwright & Co. |
| 7/26/2021 | $23.00 | Outperform | Northland Capital |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00
Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00
Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00
Mizuho initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of MiMedx Group with a rating of Buy and set a new price target of $8.50 from $20.00 previously
Northland Capital initiated coverage of MiMedx Group with a rating of Outperform and set a new price target of $23.00
H.C. Wainwright initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $20.00
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)
S-8 - MIMEDX GROUP, INC. (0001376339) (Filer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
DEFA14A - MIMEDX GROUP, INC. (0001376339) (Filer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
DEF 14A - MIMEDX GROUP, INC. (0001376339) (Filer)
10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
Fastest customizable press release news feed in the world
Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Vaporox, Inc. ("Vaporox") today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy ("VHT") device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website
MARIETTA, Ga., July 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") release of the CY 2026 Physician Fee Schedule ("PFS") proposal. "We welcome and support improvements to Medicare's reimbursement of skin substitutes across all care settings. The proposed rule, which was published yesterday afternoon, calls for a move away from the ASP methodology in favor of a fixed price per square centimeter of $125.38 for all skin substitutes. While many may take issue with the proposed price, reform in this category is long overdue," stated Joseph H. Capper, MIMEDX Chief Executive Offic
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual1:1 sessions: Wednesday, June 25, 2025 Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative. About MIMEDXMI
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. Presentation Details: Tuesday, May 13, 20255:15 p.m. PDTWebcast Link Investors interested in meeting with senior management at this event may contact their Bank of America representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wou
MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: "Placental allograft reconstruction of cutaneous wounds following Mohs surgery: a propensity score-matched comparative cost-effectiveness analysis." Mohs surgery is widely accepted as the gold standard for treating many types of skin cancer, including basal and squamous cell carcinomas, which are the most comm
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total
MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13752696 A replay of the webcast will be available for approximately 30 days on the Company's
MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. "MIMEDX's ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on full display at these high-profile conferences this spring," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "We are excited to share insights with leading wound care providers and key opinion leaders at the Diabetic Limb S
Live finance-specific insights
Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total
MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13752696 A replay of the webcast will be available for approximately 30 days on the Company's
Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are pleased today to report solid fourth quarter and full year 2024 results. With fourth quarter net sales
MARIETTA, Ga., Feb. 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2024 after the market close on Wednesday, February 26, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13751444 A replay of the webcast will be available for approximately 30 days on
Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid third quarter 2024 results include total net sales growth of 3% year-
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13748866 A replay of the webcast will be available for approximately 30 days on the Company's
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024, at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2024. Recent Operating and Financial Highlights: Second quarter 2024 net sales of $87 million, reflecting 7% growth over the prior year period.GAAP net income from continuing operat
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 31, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13747365 A replay of the webcast will be available for approximately 30 days on the Company's website
Live Leadership Updates
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a
MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has appointed Doug Rice as the Company's Chief Financial Officer, effective today. Pete Carlson, who has served in that role since March 2020, has resigned as Chief Financial Officer, also effective today. Mr. Rice joins MIMEDX after nearly a decade as the CFO of Orthofix Medical, a leading global spine and orthopedics company, following the company's recent merger with SeaSpine. Prior to Orthofix, Mr. Rice was also CFO at Vision Source, held several finance leadership roles, including at McAfee and Concentra, and started his career at PricewaterhouseCooper
MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company's manufacturing, supply chain, procurement, quality, and regulatory functions. Ms. Whitlow joins MIMEDX from Catalent, where she most recently served as President, Clinical Supply Services. "We are happy to begin 2023 with the addition of Ricci Whitlow to the MIMEDX leadership team," stated Todd Newton, MIM
Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX with over 15 years of healthcare-focused Wall Street and IR experience, most recently serving as head of IR for Cerus Corporation. "I am delighted to welcome Matt to MIMEDX," stated K. Todd Newton, MIMEDX interim Chief Executive Officer. "The breadth of Matt's experi
K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w
No Shareholder Action Required at This Time MARIETTA, Ga., April 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MiMedx" or the "Company"), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management ("Prescience Point") submitted a notice of nomination of Eiad Asbahi, Alfred G. Merriweather, Charlotte E. Sibley and William F. Spengler candidates to stand for election to MiMedx's Board of Directors at the Company's 2021 Annual Meeting of Shareholders, scheduled for May 27, 2021. MiMedx issued the following statement: "The MiMedx Board is made up of nine talented, experienced and highly eng
Noted biopharmaceutical thought leader adds academic, research and industry expertise MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced the appointment of Phyllis Gardner, M.D. to its Board of Directors. Regarded for her contributions and accomplishments across academia, biotechnology, and the healthcare industry, Dr. Gardner, a professor of medicine at the Stanford University School of Medicine and distinguished business leader, brings to MiMedx more than 35 years of experience, marked by numerous national awards and honors.
This live feed shows all institutional transactions in real time.
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13D/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13D/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13D - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)